Blending Site-Based and Virtual Approaches in Rare Disease Trials

Introduction: Why Hybrid Trials Are Ideal for Rare Diseases

Rare disease trials often face significant logistical hurdles—patients may live far from trial centers, travel burdens are high, and access to specialized sites is limited. To address these challenges, hybrid clinical trial models are gaining traction. These designs combine the best of both worlds: traditional site visits for critical assessments and decentralized methods (e.g., remote monitoring, telehealth) for improved flexibility and reach.

Hybrid trials are particularly valuable in rare disease research due to small, geographically dispersed patient populations and the high need for personalized protocols. They support better recruitment, patient-centricity, and retention—all while ensuring regulatory compliance and data quality.

Core Components of a Hybrid Trial Design

Hybrid clinical trials typically include a combination of the following elements:

• In-Person Visits: For baseline assessments, imaging, biopsies, or drug infusions
• Remote Visits: Through video calls or telehealth platforms for follow-up, adverse event (AE) monitoring, or questionnaires
• Home Health Visits: Certified nurses visit patients for physical assessments, sample collection, or drug administration
• Digital Tools: Wearables, ePRO apps, and remote monitoring devices to collect real-time data

For example, a hybrid study on a lysosomal storage disorder may involve three initial hospital visits followed by monthly home health nurse assessments and real-time symptom tracking via an eDiary.

Continue Reading: Regulatory Acceptance, Case Studies, and Feasibility

Regulatory Acceptance of Hybrid Trials in Rare Diseases

Both the FDA and EMA have shown openness to decentralized and hybrid elements, particularly post-COVID. However, they emphasize data reliability, GCP compliance, and clear risk management plans. For rare diseases, where trials are inherently more complex, regulators encourage sponsors to:

• Justify which trial components are remote vs. on-site
• Ensure consistency in endpoint assessment regardless of location
• Document training procedures for telehealth and remote devices
• Define how protocol deviations (e.g., missed virtual visits) are handled

The EMA’s “Reflection Paper on Decentralised Elements” and the FDA’s guidance on decentralized clinical trials both highlight the importance of patient safety, data traceability, and sponsor oversight when implementing hybrid methods.

Case Study: Hybrid Model in a Rare Neuromuscular Disorder Trial

A U.S.-based Phase II trial evaluating an antisense oligonucleotide in patients with Spinal Muscular Atrophy (SMA) used a hybrid design that included:

• Initial site-based baseline visit and drug administration
• Monthly nurse home visits for follow-up assessments
• Wearables to monitor motor activity and breathing patterns
• ePRO for patient-reported fatigue and mobility outcomes

The model helped the trial achieve a 90% retention rate and reduced site visit burden by 60%, especially important for participants using wheelchairs or ventilatory support. Data consistency was maintained through device calibration protocols and central monitoring.

Technology Infrastructure and Data Integration Challenges

Implementing hybrid trials requires a robust technological backbone to manage distributed data sources and ensure interoperability. Key considerations include:

• Electronic Data Capture (EDC): Must integrate inputs from wearables, home visit nurses, and site coordinators
• Telemedicine Platforms: Should be secure, compliant (e.g., HIPAA/GDPR), and user-friendly for patients and caregivers
• Data Standardization: Variability in device outputs must be minimized through calibration and consistent protocols
• Audit Trails and Traceability: Every data point must be attributable, legible, contemporaneous, and verifiable (ALCOA)

For example, data from a wearable spirometer and a home nurse’s paper-based assessment must be harmonized and entered into the central database following validation rules and timestamps.

Feasibility Assessment for Hybrid Models in Rare Diseases

Before implementing hybrid models, sponsors should conduct feasibility assessments tailored to the rare disease population. This includes:

• Identifying tasks that can be safely and accurately done remotely
• Assessing geographic distribution of the patient population
• Evaluating caregiver burden and access to home internet/technology
• Conducting surveys or advisory board meetings with patient advocacy groups

For instance, in a trial targeting a pediatric rare epilepsy, it may be inappropriate to rely solely on parent-reported ePRO for seizure frequency without confirmation from EEG data captured at clinical sites.

Ethical and Data Privacy Considerations

Hybrid designs raise specific ethical and data protection concerns, especially in rare diseases where data may be more easily linked to individuals. Key elements include:

• Ensuring patients are fully informed about data collection methods during consent
• Using pseudonymization and encryption for all remote data transmission
• Minimizing video recording unless essential for clinical outcomes
• Establishing role-based access controls and SOPs for decentralized teams

Any deviation from in-person protocols must be justified and approved by institutional review boards (IRBs) or ethics committees.

Benefits of Hybrid Models for Ultra-Rare and Pediatric Conditions

Hybrid designs offer special advantages in pediatric and ultra-rare indications:

These models reduce trial dropouts and enable broader demographic inclusion—both of which are critical for generalizable results in rare indications.

Conclusion: A Patient-Centric Path Forward

Hybrid clinical trials are not just a temporary adaptation but a future-proof solution for rare disease research. They align with regulatory expectations, enhance patient access, and enable data collection across diverse and dispersed populations.

By investing in scalable infrastructure, prioritizing data integrity, and co-designing studies with patient communities, sponsors can implement hybrid models that are both scientifically robust and ethically sound.

Platforms such as Be Part of Research (NIHR) increasingly highlight hybrid-enabled studies to improve visibility and enrollment.

Ultimately, hybrid trial models bring rare disease research closer to the patient—literally and figuratively—making meaningful progress toward faster, fairer, and more flexible clinical development.

How Wearable Technologies are Revolutionizing Rare Disease Clinical Trials

The Role of Wearables in Rare Disease Research

Rare disease clinical trials face challenges such as small populations, geographically dispersed patients, and the need for long-term monitoring. Wearable devices—ranging from wristbands and accelerometers to advanced biosensors—are increasingly being adopted to overcome these barriers. They offer continuous, real-world data collection on patient activity, vital signs, and disease-specific endpoints, reducing the burden of frequent site visits.

For example, activity trackers can quantify mobility in patients with neuromuscular disorders, while wearable ECG patches can monitor arrhythmias in rare cardiac conditions. These technologies provide objective, high-frequency data that surpass traditional clinic-based assessments. By capturing real-world fluctuations in symptoms, wearables improve endpoint sensitivity and statistical power in small patient cohorts.

Regulatory agencies such as the European Medicines Agency are publishing guidance on digital endpoints, reinforcing the acceptance of wearables as valid data sources in regulatory submissions. This shift is crucial in rare disease research, where every data point contributes significantly to trial outcomes.

Types of Wearable Devices and Their Applications

Wearables used in rare disease clinical trials can be categorized based on functionality:

• Activity Monitors: Accelerometers and actigraphy devices that measure gait, mobility, and fatigue—valuable in diseases such as Duchenne muscular dystrophy (DMD).
• Cardiac Sensors: Wearable ECG and pulse oximetry devices, used in rare genetic arrhythmias or pulmonary hypertension studies.
• Neurological Monitors: Smart headbands and EEG wearables that track seizure activity in rare epileptic syndromes.
• Respiratory Sensors: Chest patches or spirometry-enabled wearables monitoring lung function in cystic fibrosis or rare interstitial lung diseases.
• Biochemical Monitors: Continuous glucose monitoring adapted for metabolic rare diseases like glycogen storage disorders.

Each device type is chosen to align with the disease pathology and trial endpoints. For instance, in an ultra-rare neuromuscular disease, step-count decline measured by an accelerometer over 12 months may serve as a primary endpoint, replacing more burdensome 6-minute walk tests.

Case Study: Wearables in Duchenne Muscular Dystrophy Trials

A notable case is the use of actigraphy in DMD clinical trials. Traditionally, DMD progression was monitored using clinic-based tests, but these failed to capture daily functional decline. Actigraphy devices worn 24/7 provided continuous mobility data, revealing early signs of disease progression months before conventional measures. This improved trial sensitivity and reduced sample size requirements, critical for a population of only a few thousand patients worldwide.

The data also enhanced patient engagement, as families reported satisfaction with non-invasive, home-based monitoring compared to frequent site visits. This model demonstrates how wearables can simultaneously improve data quality and patient experience.

Regulatory and Data Integrity Considerations

While promising, wearable device integration must comply with strict regulatory and ethical standards. Issues include:

• Data Privacy: Continuous monitoring generates sensitive personal health data, requiring compliance with GDPR, HIPAA, and other frameworks.
• Device Validation: Devices must be clinically validated, with performance metrics documented in trial protocols and regulatory submissions.
• Data Integrity: Sponsors must demonstrate secure data transmission, audit trails, and tamper-proof storage to meet GCP requirements.
• Patient Consent: Participants must be fully informed of the scope and risks of continuous monitoring.

These requirements highlight the need for robust device qualification programs and close collaboration with regulators during trial design.

Integration with Clinical Trial Infrastructure

For wearables to be effective, data must be integrated into existing clinical trial management systems (CTMS) and electronic data capture (EDC) platforms. Sponsors increasingly use APIs to link wearable data streams with trial dashboards, allowing real-time monitoring by investigators. Advanced analytics platforms can flag safety signals or adherence issues, enabling early intervention.

A dummy example of wearable data integration:

Future Directions: Digital Biomarkers and Decentralized Trials

The next frontier is the development of digital biomarkers validated for regulatory acceptance. Wearables will increasingly measure complex endpoints, such as tremor variability in rare neurological diseases or nighttime hypoxia in metabolic disorders. These biomarkers can provide surrogate endpoints, accelerating regulatory approvals for orphan drugs.

Moreover, wearables are integral to decentralized trial models. Patients can participate from their homes while transmitting continuous data to trial centers. This model reduces travel burdens and improves inclusivity, particularly in ultra-rare diseases with geographically scattered patients. Experts predict that by 2030, more than half of rare disease studies will rely on hybrid or decentralized approaches supported by wearables.

Conclusion: A Paradigm Shift in Rare Disease Clinical Research

Wearable devices represent a paradigm shift in rare disease clinical trials by improving data richness, reducing patient burden, and enabling decentralized participation. Sponsors adopting wearable-enabled endpoints will accelerate trial timelines, enhance regulatory acceptance, and ultimately bring treatments faster to underserved patient populations. As validation frameworks strengthen, wearables are set to become indispensable tools in the future of rare disease clinical development.